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Cyclosporin AHuman malignant glioblastomas are highly invasive tumors. Increased cell motility and degradation of the
surrounding extracellular matrix are essential for tumor invasion. PI3K/Akt signaling pathway emerges as a
common pathway regulating cellular proliferation, migration and invasion; however, its contribution to
particular process and downstream cascades remain poorly deﬁned. We have previously demonstrated that
Cyclosporin A (CsA) affects glioblastoma invasion in organotypic brain slices and tumorigenicity in mice. Here
we show that CsA impairs migration and invasion of human glioblastoma cells by downregulation of Akt
phosphorylation. Interference with PI-3K/Akt signaling was crucial for CsA effect on invasion, because
overexpression of constitutively active myr-Akt antagonized drug action. Furthermore, the drug was not
effective in T98G glioblastoma cells with constitutively high level of phosphorylated Akt. CsA, comparably to
pharmacological inhibitors of PI3K/Akt signaling (LY294002, A443654), reduced motility of glioblastoma
cells, diminished MMP-2 gelatinolytic activity and MMP-2 and MT1-MMP expression. The latter effect was
mimicked by overexpression of dominant negative Akt mutants. We demonstrate that CsA and LY294002
reduced MMP transcription partly via modulation of IκB phosphorylation and NFκB transcriptional activity.
Those effects were not mediated by inhibition of calcineurin, a classical CsA target. Additionally, CsA reduced
phosphorylation and activity of focal adhesion kinase that was associated with rapid morphological
alterations, rearrangement of lamellipodia and impairment of MT1-MMP translocation to membrane
protrusions. Our results document novel, Akt-dependent mechanisms of interference with motility/invasion
of human glioblastoma cells: through a rapid modulation of cell adhesion and MT1-MMP translocation to
membrane protrusions and delayed, partly NFκB-dependent, downregulation of MMP-2 and MT1-MMP
expression.ka).
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
The invasion of neoplastic cells into brain parenchyma and fast
proliferation are hallmarks of glioblastomas, themost malignant brain
tumors [1,2]. In order to penetrate brain parenchyma glioma cells
generate actin-rich membrane protrusions with extracellular matrix
(ECM) proteolytic activity such as lamellipodia and invadopodia.
These dynamic structures penetrate the microenvironment, anchor
motile cells by focal adhesions and release proteinases that degrade
ECM. Invasiveness and migration are complex processes which are
regulated by phosphoinositide 3-kinase (PI3K), downstream Akt
kinase and focal adhesion kinase (FAK) signaling pathways [3–5].
Binding of ECM proteins or growth factor receptor activation triggers
focal adhesion kinase phosphorylation initiating focal adhesionsturnover [6–10] and allows PI 3-kinase recruitment to the membrane
and stimulation of Akt signaling [2,6]. PI3K/Akt signaling enhances
actin remodeling and formation of membrane protrusions inﬂuencing
Rac proteins [11], and through the activation of p70S6Kmodulates cell
migration and invasion [12]. Akt is localized at the leading edge of
moving cells in actin-rich structures and interacts with actin binding
proteins [4,13]. Downregulation of Akt expression (in particular Akt2)
with antisense or dominant negative constructs resulted in inhibition
of glioma cell invasion in vitro [14] and in vivo [15]. The expression of
matrix metalloproteinases (MMPs)-2 and -9 was inhibited in the rat
tumor tissue with reduced Akt2 expression [15].
Local modiﬁcation of ECM by the peptidases in gliomas involves
the plasminogen activators, matrix metalloproteinases and cathe-
psins. Among various MMPs, the increased expression of the
gelatinases MMP-2 and MMP-9 strongly correlates with glioma
progression [16–18] and malignancy [19–21]. Physiological levels of
MMPs are low and the amount of active enzyme is tightly regulated at
several levels that involve regulation of gene expression, activation of
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[20,22]. The expression of many MMPs and their inhibitors TIMPs
(tissue inhibitor of metalloproteinases) is regulated by transcriptional
and post-transcriptional mechanisms by a variety of growth factors,
cytokines and chemokines [23–26]. Membrane bound MT-MMPs, in
particular membrane-type MT1- and MT2-MMP, play a major role in
activating MMP-2. Newly synthesized MMP-2 is secreted as an
inactive pro-enzyme, which is cleaved on the cell surface by
membrane-type MT1-MMP (MMP-14) complexed with TIMP-2
[17,19,27,28]. Development of pharmaceutical approaches that affect
expression or regulation of MMPs may be beneﬁcial in targeting
invasion of glioma cells but speciﬁc inhibitors are still to be found.
We have previously demonstrated that cyclosporin A (CsA), a
calcineurin inhibitor, affects growth of glioma cells [29–32] and
downregulates PI3K/Akt signaling and Akt-dependent phosphorylation
of downstream targets [33]. Moreover, at low micromolar concentra-
tions CsA suppresses glioma cell invasion in vitro, in organotypic brain
slice cultures, and reduces tumorigenicity in vivo [34]. We showed that
CsA may directly block glioma invasion without affecting cell prolifer-
ation or viability.
In the present study we studiedmolecularmechanisms underlying
the inhibitory effect of CsA on migration/invasion of human
glioblastoma cells with different alterations of PI3K/Akt signaling
pathway and contribution of PI3K/Akt signaling in the regulation of
tumor cell migration and invasion. We demonstrate that CsA impairs
Akt and FAK signaling that results in reduction of motility and
invasion of glioblastoma cells. CsA, as well as pharmacological and
genetic inhibitors of PI3K/Akt signaling, reduced invasion and MMP-2
proteolytic activity likely in two mechanisms: by rapid impairment of
shuttling MT1-MMP to lamellipodia and delayed downregulation of
NFκB-dependent MMP expression. Our ﬁndings show for the ﬁrst
time anti-invasive action of CsA and deﬁne a complex involvement of
Akt signaling into the regulation of cellular motility and invasion.
2. Materials and methods
2.1. Cell cultures
Human glioblastoma cell lines LN229, T98G and U373 (ATCC,
Manassas, VA) were cultured in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum (Gibco, MD,
USA) and antibiotics (50 U/ml penicillin, 50 μg/ml streptomycin) in a
humidiﬁed atmosphere of CO2/air (5%/95%) at 37 °C (Heraeus, Hanau,
Germany).
2.2. Reagents
Antibodies recognizing phosphorylated forms of Akt (Thr308/
Ser473), IκB (Ser32), FAK (Thr925/Thr397), GSK3β (Ser-9), as well as
corresponding anti-total Akt, IκB, FAK, GSK3β, antibodies and
horseradish peroxidase-conjugated anti-rabbit IgG were purchased
from Cell Signaling Technology (Beverly MA, USA). For MMPs
Western blot, antibodies anti-MT1-MMP from Chemicon Intern. and
anti-MMP-2 from Santa Cruz Biotechnology were used. Immunocom-
plexes were detected using enhanced chemiluminescence detection
system (ECL). Cyclosporin A was from Novartis (Novartis Pharma
GmbH Nurnberg, Germany), LY294002 was from Cell Signaling
Technology (Beverly MA, USA), FK506 (Prograf) from Fujisawa
GmbH (Monachium, Germany) and BAY11-7082 was purchased
from Sigma Aldrich Inc. (St. Louis, MO). A-443654–Akt inhibitor was
a kind gift from Dr. V. Giranda, Abbott Laboratories.
2.3. Western blot analysis
Whole-cell lysates were prepared as previously described [35].
Cells were lysed in a buffer containing 20 mM Tris, pH 6.8, 137 mMNaCl, 2 mM EDTA, 25 mM glycerophosphate, 2 mM NaPPi, 1 mM
Na3VO4, 1% Triton X-100, 10% glycerol, 5 μg/ml leupeptin (Sigma),
5 μg/ml aprotinin (Sigma), 2 mM benzamidine and 0.5 mM DTT
(Roche Applied Science). The cell lysates were centrifuged and the
protein concentration was evaluated with BCA protein assay (Pierce).
Total protein extracts (50 μg of proteins) were mixed with
5×Laemmli buffer (50 mM Tris–HCl pH 6.8, 100 mM DTT, 10%
glicerol), denaturated by boiling for 10 min and equivalent amounts
of protein were loaded onto 4–10% Tris glycine/SDS-polyacrylamide
gels and electrotransferred to ECL nitrocellulose membranes. The
speciﬁc antibodies as indicated were used for immunoblots. Primary
antibodies were detected with either anti-mouse IgG or anti-rabbit
IgG antibody linked to horseradish peroxidase (Sigma). Immunocom-
plexes were visualized by ECL (Amersham Pharmacia Biotech). Bands
intensity was determined by densitometry with BioRad Molecular
Imager FX and Quantity One software.
2.4. Measurements of cell viability and proliferation
LN229, T98G and U373 cells (8×104 cells/well) were seeded in 24-
well plates, incubated overnight and treated with CsA for next 12 or
24 h, respectively. Then MTT metabolism test was performed as
previously described [36]. Cell proliferation was determined with
BrdU assay. Cells were seeded in 96-well plates (6×103 cells/well),
transfected with speciﬁc plasmids and after overnight incubation at
37 °C. Cells were treated for 2 h with BrdU labeling solution (Cell
Proliferation ELISA BrdU assay, Roche Diagnostics GmbH Mannheim,
Germany), ﬁxed and incubated with a mouse monoclonal anti-BrdU
antibody conjugated with peroxidase. Adding 1 M H2SO4 enables
photometric detection by Thermo labsystem Multiscan EX at 450 nm.
2.5. Plasmids, transfection and gene reporter assay
LN229 cells (8×104 cells/well) were seeded on 24-well plates 24 h
before transfection. Cells were transfected using Lipofectamine™
2000 Reagent (Invitrogen, Carlsbad, CA) with the plasmid carrying a
ﬁreﬂy luciferase gene under promoter consisting multiple binding
sites for NFκB (NF-κB cis-Reporting System, Stratagene-Agilent
Technologies Company, CA, USA). After cell lysis the luciferase activity
was measured using Luciferase Reporter Assay System (Promega
Corporation Madison, WI, USA) according to manufacturer's protocol.
The plasmid coding for wtAktwas a kind gift fromDr. T. Franke and
was previously described [33,37,38]. Plasmid encoding constitutively
active myrAkt was kind gift from Dr. M. Weber [33,39]. LN229 cells
were transfected using Cell Line Nucleofector™ Kit V according to
manufacturer's protocol. Twenty-four hours after transfection cells
were detached with 0.25% trypsin/0.02% EDTA (Sigma), counted and
used in the matrigel invasion or BrdU assays.
The plasmids coding for dominant negative Akt mutants: ΔPHAkt
and K179MAkt were kind gifts from Dr. T. Franke and have been
previously described [37,38]. The K179MAkt construct contains a
point mutation within the ATP-binding pocket rendering the kinase
inactive and theΔPHAkt construct has the plecstrin homology domain
of Akt deleted activation. The LN229 cells were transfected using Cell
Line Nucleofector™ Kit V following manufacturer's protocol. Forty-
eight hours later total RNA was isolated and used as a template in
RT-PCR.
2.6. Invasion and migration assays
The invasion assay was performed as described [34,40]. Brieﬂy,
24-well tissue culture inserts (12 μm pore size Transwell, Corning, NY,
USA) coated with the Growth Factor Reduced Matrigel™ Matrix (BD
Biosciences, San Diego. CA, USA) were used. One hundredmicroliters of
the Matrigel™ Matrix (1 mg/ml) diluted in distilled water, was dried
under sterile conditions (37 °C) for 5–6 h and reconstituted for 30 min
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were seeded in the number of 1.5×104/insert on matrigel-covered
membrane in serum-reduced medium (2% FBS) and treated with 1 μM
or 5 μM CsA or left untreated. After 12 or 18 h cells were ﬁxed and cell
nuclei stained with DAPI (4′,6-Diamidino-2-Phenylindole; 0.01 mg/ml,
Sigma). The membranes from Transwell® inserts were cut out and the
total number of invading cells that migrated through the Matrigel was
determined using Laser Scanning Cytometry (LSC, CompuCyte). The
resultswere conﬁrmed bymanual blind counting. All experimentswere
performed three times, in triplicate.
For a scratch assay, LN229 cells were plated in 6-well plate and
cultured overnight in DMEM containing 10% of FBS to reach 90%
conﬂuence. Cell monolayer was wounded with a sterile Eppendorf
pipette tip (100 μl), washed with PBS, then fresh 2% serum
containing medium was added to control plates and supplemented
with 5 μM CsA to treated plates. Cells were incubated for 18 h, ﬁxed
with 2% paraformaldehyde, stained with DAPI or phalloidin and
visualized by ﬂuorescent microscopy. The nuclei of cells migrating
to the cell-free area of scratch in randomly selected ﬁelds were
counted.
For analysis of cell migration using live cell imaging the monolayer
of cells was scratched using a sterile pipette tip (10 μl) and after
washing with PBS cells were treated with 5 μM CsA, 1 μM A-
443654, 30 μM LY294002 or corresponding amounts of DMSO as a
control. The cultures were placed in a 37 °C chamber equilibrated with
humidiﬁed air containing 5% CO2 throughout the experiment. Time
lapsemicroscopy was performed with a Leica DMIR 2microscope using
a 20× objective. Images were taken with Micromax YHS 1300 camera
(pixel of 6.7. μm) at 30 min intervals for 24 h. Pictures were analyzed,
and the total distance and the velocity were calculated using
Metamorph 6 and Image J.2.7. Real-time PCR
Total RNA (2 μg) isolated from LN229 cells treated with various
inhibitors (CsA, BAY11-7082, LY294002) or transfected with plasmids
coding for ΔPHAkt or K179MAkt was used as a template to generate
cDNA. Then MMP-2 and MT1-MMP genes were ampliﬁed using
primers (Hs00234422_m1) and (Hs00237119_m1) respectively. Taq-
Man MGB probe was marked with FAM™ reporter dye at the 5′ end
and nonﬂuorescent quencher at the 3′ end of the probe. As
endogenous control 18S (Hs99999901_s1) rRNA was applied. Gene
expression quantiﬁcationwas performed using the Applied Biosystem
TaqMan® Gene Expression Assay with the following parameters:
stage 1 (50 °C for 2 min) 1 cycle, stage 2 (95 °C for 10 min) 1 cycle,
stage 3 (95 °C for 15 s, 60 °C for 1 min) for 40 cycles. Data were
analyzed by the Relative Quantiﬁcation (ΔΔCt) method using 7500
System SDS software (Applied Biosystems). The expression of each
product was normalized to 18S rRNA and is shown as the ratio of the
target gene to 18S gene expression, calculated by 2−ΔΔCt.2.8. Gelatin zymography
LN229 cells were treated with control medium alone or supple-
mented with 5 μM CsA, 5 μM FK506 or 30 μM LY294002. Conditioned
media were collected and samples were prepared in non-denaturat-
ing conditions in 5× Laemmli buffer without DDT. Samples were
resolved in 8% SDS-PAGE gel containing 2 mg/ml of gelatin (SIGMA–
ALDRICH CO, USA). The gels were washed twice in 2.5% Triton X-100
at room temperature before overnight incubation in renaturation
buffer (50 mM Tris–HCl pH 7,6; 10 mM CaCl2; 1 μM ZnCl2; 1% Triton
X–100 and 0.02% sodium azide). Gels were stained with Coomasie
brilliant blue and band intensities were determined densitometrically
with BioRad Molecular Imager FX and Quantity One software.2.9. Immunocytochemistry
LN229 cells were seeded in 8 chamber Polystyrene Vessel Culture
slides (BD Falcon) 4×104 cells per chamber. The next day monolayer
of cells was scratched, cells were washed with PBS and cultured in the
presence or absence of 5 μMCsA or 30 μMLY294002 for 6 h. Following
ﬁxation with 2% p-formaldehyde for 20 min at room temperature,
cells were washed three times with PBS and permeabilized 1 h with
0.5% Triton X-100, followed by 90-min incubation in a blocking buffer
(4% BSA, 3% NGS in 0.1% Triton X-100 in PBS). Subsequently, cells were
incubated overnight at 4 °C with antibodies against MT1-MMP
(Chemicon International, 1:100), phospho-paxilin (Tyr118, Cell
Signaling, 1:50) or phospho-ezrin (Tyr354, Santa Cruz Biotechnology,
1:100). Next day cells were washed with 0.1% Triton X-100 in PBS for
5 min and incubated with a secondary antibody labeled with FITC.
Cells were also stainedwith a Rhodamine–phalloidin (1 μg/ml, Sigma)
dissolved in PBS. Subcellular localization of MT1-MMP and F-actin
distribution pattern were analyzed using confocal microscopy.
2.10. Statistical analysis
Each experiment was performed at least 3 times, on independent
passages, usually in triplicates. Data were analyzed by Newman–
Keuls test using Statistica software as indicated and are presented as
mean±SEM. pb0.05 was considered statistically signiﬁcant. Results
of time lapse microscopy experiments were analyzed with Wilcoxon
test in R software.
3. Results
3.1. Cyclosporin A reduces invasion and motility of LN229 glioblastoma
cells
In the present work invasion through matrigel, a matrix extract of
non-crosslinked ECM macromolecules was used to evaluate effect of
CsA on invasion of human LN229 glioblastoma cells. We developed a
modiﬁed, quantitative matrigel invasion assay, in which the nuclei of
cells migrating through matrigel to the lower surface of the
membrane were stained with DAPI. The blue emission of DAPI-
stained DNA was measured using laser scanning cytometry (iCys;
CompuCyte, Cambridge, MA) with standard ﬁlter settings (Fig. 1A).
The number of invading LN229 glioblastoma cells signiﬁcantly
decreased in cultures treated for 18 h with 5 μM CsA in comparison
with untreated cultures (Fig. 1B). The observed reduction in the
number of invading cells was not due to decrease in cell proliferation
or cytotoxicity, because CsA applied at such concentrations did not
affect the viability of cells, as determined by MTT metabolism test
(Fig. 1C). The effect of CsA on cell migration was examined using a
“scratch assay”. Quantiﬁcation of cell migrating to cell-free areas along
a scratch revealed that the number of cells migrating to cell-free area
was reduced to 60% in cultures treated with 5 μM CsA in comparison
to controls (Fig. 1D).
3.2. CsA affects glioblastoma invasion/motility by interference with
PI3K/Akt signaling pathway
Treatment of cells with 5 μM CsA led to a rapid reduction of the
level of phosphorylated Thr308 Akt, starting as early as 30 min after
treatment (Fig. 2A). Six hours after treatment with 5 μMCsA the levels
of Akt phosphorylated at Thr308 and Ser473 were barely detectable.
These results were conﬁrmed by densitometric analysis of immuno-
blots from 3 independent experiments (Fig. 2A, lower panel).
To study if downregulation of PI3K/Akt signaling pathway by CsA
is crucial for this effect, the constitutively active myristylated Akt
(myrAkt) or the wild type Akt (wtAkt) were overexpressed in LN229
cells and CsA effect on invasion of transfected cells was analyzed. Cell
Fig. 1. Cyclosporin A reduces invasion andmigration of human glioblastoma LN229 cells. A. LN229 cells plated on amatrigel-coated Boyden chamber were cultured for 18 h in DMEM
with 2% FBS in the presence or absence of 1 or 5 μM CsA. Cells migrating through matrigel were ﬁxed, their nuclei stained with DAPI and counted with Laser Scanning Cytometry.
Representative LSC histograms are shown. B. Quantiﬁcation of migrating cells (means±SEM; 3 independent experiments, each in triplicate; *pb0.05 CsA vs. ctrl). C. CsA does not
affect cell viability as assessed by MTT metabolism test, means±SEM; 3 experiments, each in triplicate. D. Cell motility is impaired by CsA as determined with a “scratch” assay.
Nuclei of migrating cells were stained with DAPI and counted under the ﬂuorescent microscope with the excitation 330–380 nm. Cells from 16 ﬁelds were counted and are presented
as means±SEM, n=4 experiments, each in triplicate.
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transfection efﬁciency. Overexpression of myrAkt abolished the
inhibitory effect of CsA on cell invasion when compared with of
mock or the wild-type Akt transfected cells (Fig. 2B). Cell proliferation
of transfected cells was evaluated using BrdU incorporation test to
exclude that overexpression of wtAkt or myrAkt affects proliferation
of LN229 cells changing the number of cells (Fig. 2C).
Invasion of PTEN-mutated T98G glioblastoma cells and PTEN-null
U373 cells, exhibiting constitutively high level of phosphorylated Akt,
have been analyzed. Most T98G and U373 cells migrated through
matrigel during 12 h and CsA treatment did not affect their
invasiveness or cell viability (Fig. 3A). In parallel, the levels of
phosphorylated Akt remained unaffected in CsA-treated T98G and
U373 cells (Fig. 3B and the supplementary Fig. 1). Thus, over-
expression of constitutively active Akt in LN229 cells or persistent Akt
phosphorylation in PTEN-deﬁcient cells abolished the inhibitory effect
of CsA on glioblastoma invasion.
Live cell imaging technology was employed to analyze cell motility
during scratch-induced migration. LN229 glioma cells were incubatedwith CsA, LY294002—an inhibitor of PI3 kinase, or A443654—an
inhibitor of Akt kinase [41]. The inhibitory effect of A443654 on Akt
activity was determined indirectly by measuring its ability to reduce
GSK-3β phosphorylation (Supplementary data). Quantiﬁcation of the
results showed that cell migration was signiﬁcantly reduced in CsA,
LY294002 or A443654 treated cultures, and CsA was as effective as
classical Akt signaling inhibitors. The reduction of speed was constant
throughout 24 h of the experiment. The total distances calculated for
200 cells from each of experimental condition are presented in Fig. 4.
3.3. Direct effect of CsA on cell motility and morphology of LN229
glioblastoma cells
Actin assembly at the cell front drives membrane protrusion and
initiates a directional cell migration. Microtubules extend forward
within protrusions to sustain cell polarity and promote adhesion site
turnover. To determine whether reduced cell motility in CsA-treated
cultures is associated with cytoskeleton rearrangements, phalloidin
staining of F-actin was performed. Several hours after scratch, control
Fig. 2. Decrease of cell invasion in CsA-treated LN229 cultures is due to downregulation of PI3K/Akt signaling. A. LN229 cells were treated with CsA and total protein extracts were
collected. Immunoblots were probed with antibody recognizing total or phosphorylated Akt and re-probed with anti-β-actin antibody. Densitometric analysis was performed and
phosphorylated/total kinase ratiowas calculated (means±SEM, n=3). B. LN229 cells were detached by trypsinization 24 h after transfection with plasmids encoding GFP, thewild-type
Akt (wtAkt) or the constitutively activeAkt (myrAkt) and seededonmatrigel covered inserts inDMEMwith 2%FBSwith orwithout 5 μMCsA. After 18 h cells invadingmatrigelwereﬁxed,
stained with DAPI and counted with LSC (means±SEM; n=3, each in triplicate). C. Cell proliferation was determined with a BrdU proliferation test in transfected cells.
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actin clusters, mostly at the leading edge (Fig. 5A, indicated by white
arrows). Numerous rufﬂed membrane extensions (lamellipodia),
characteristic feature of moving cells, were observed. On the contrary,
cells treated with CsA were ﬂattened with visible, stretched actin stress
ﬁbers and such phenotype was preserved for several hours (Fig. 5A).
A key regulator of cell movement and focal contact turnover is
focal adhesion kinase (FAK) [6,8]. Paxilin, a focal adhesion-associated
protein, functions downstream to FAK as an adaptor protein recruiting
diverse cytoskeleton and signaling proteins into a adhesion complex
(including ezrin that binds to plasma membrane and F-actin).
FAK-deﬁcient cells exhibit a refractory cell motility, in part due to
enhanced stability of focal adhesions [8,10]. To assess if CsA affects
FAK activity, Western blot analysis of FAK autophosphorylation at
Tyr397 and subsequent phosphorylation of Tyr925 (reﬂecting the
kinase activity of FAK and its phosphorylation by Src) was
performed. As shown in Fig. 5B–C, the phosphorylation of both
residues within FAK, which represents FAK activity, was strongly
decreased in LN229 cells treated with 5 μM CsA; the level of total
FAK was unaffected. Reduction in the FAK activity correlated in
time with changes in the levels of phospho-paxilin (Tyr118) after
CsA treatment. Detection of phospho-paxilin and phospho-ezrin
by immunoﬂuorescence evidenced changes in their localization
and disappearance of ezrin-marked lamellipodia in CsA-treated
cultures (supplementary Fig. 2).
Deregulation of FAK phosphorylation and activity may lead to
dysfunction of adhesion contacts during cell movement. Paxilin is oneof the cytoskeletal components of the focal adhesion and a direct
substrate of FAK. Immunoblot and densitometry show the reduction
of the level of phosphorylated paxilin (Tyr118 in CsA-treated cultures
(Fig. 5C). Immunoﬂuorescence for phospho-ezrin (Tyr353), another
substrate of FAK and protein abundant in invadopodia, demonstrated
diffused staining and disorganization of adhesion contacts in CsA-
treated cultures (Supplementary data 2).3.4. CsA reducesMMP-2 activity and downregulatesMMP-2 andMT1-MMP
expression in LN229 glioblastoma cells
Elevated levels of MMP-2 expression and activity correlate both
with increased invasiveness of glioma cell lines [42] and with tumor
grade [43]. Therefore, conditioned media from LN229 cultures
untreated or treated for 18 and 24 h with 5 μM CsA or 30 μM
LY294002 were collected and processed for gelatin zymography. The
effect of CsA on proteolytic activity of MMP-2 was clearly visible
(Fig. 6A and B), in contrast to barely detectable pro-MMP-2 or MMP-9
(data not shown). The amount of active MMP-2 was reduced in
cultures treated with 5 μM CsA or 30 μM LY294002 (Fig. 6A).
Quantiﬁcationof densitometric results from3 independent experiments
conﬁrmed 30–40% reduction of the MMP-2 gelatinolytic activity in
drug-treated cultures 18–24 h after treatment. FK506, a calcineurin
inhibitor unrelated to CsA, did not affect activity of MMP-2, suggesting
that an inhibitory effect of CsA does not rely on calcineurin inhibition
(Fig. 6B).
Fig. 3. CsA fails to reduce invasiveness of human T98G glioblastoma cells with constitutively high Akt phosphorylation. A. Upper panel: Representative pictures of T98G cells invading
matrigel for 12 h.Cellswereﬁxed, their nuclei stainedwithDAPI and countedbyLSC. Lowerpanel:Quantiﬁcationof results of T98GandU373cell invasionandproliferation (means±SEM,
n=3 experiments, each in triplicate). B. The inﬂuence of CsA on viability of glioblastoma cells determined usingMTTmetabolism test. The levels of total and phosphorylated Akt in T98G
cells cultured in the presence or absence of CsA. Ratio of phosphorylated/total kinase calculated after densitometric analysis of immunoblots (means±SEM, n=3).
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membrane type 1 MMP (MT1-MMP) and tissue inhibitor of MMP-2
(TIMP-2) followed by processing of pro-MMP-2 byMT-MMP [44]. Since
transcription of MMPs may be a rate-limiting factor in MMP-2
regulation, we analyzed the levels of MMP-2 and MT1-MMP mRNA
in LN229 cells under various conditions using a quantitative RT-PCR. A
signiﬁcant reduction of MMP-2 mRNA level was observed 24 and 48 h
after treatment, whileMT1-MMPmRNA level decreased by 40% at later
time point. At earlier time points MMP-2 and MT1-MMP mRNA levels
were similar in untreated and CsA-treated cells (Fig. 6C and D).
The inﬂuence of PI3K/Akt signaling pathway on expression of
MMP-2 and MT1-MMP was further analyzed in cells incubated with
LY294002 or transfected with plasmids coding for dominant negative
Akt mutants (ΔPHAkt or K179MAkt). Treatment with LY294002 or
overexpression of dominant negative Akt kinase reduced the levels of
both of MMP-2 and MT1-MMPmRNAs, indicating that the expression
of these genes is regulated by Akt (Fig. 7A and B). Moreover, treatment
of LN229 cells with BAY11-7082 (an irreversible inhibitor of IκBα
phosphorylation) for 24 h strongly reduced the expression of MMP-2
(Fig. 7C) suggesting that it depends on NFκB signaling. An inhibitory
effect of BAY11-7082 on MT1-MMP mRNA synthesis was observed
only 48 h after treatment (data not shown). Results of Western blot
analysis corroborate gene expression data and show the reduced level
of MT1-MMP in CsA- and LY294002- but not BAY11-7082-treated
cultures. The expression of MMP-2 was mainly reduced by LY294002;
however, both CsA and BAY11-7082 reduced theMMP-2 level to some
extent (Fig. 7D).3.5. CsA downregulates NFκB activation and transcriptional activity via
interference with PI-3/Akt signaling pathway
Correlation between increased Akt phosphorylation and high levels
of NFκB activity in malignant gliomas has been reported [45]. The
promoter regions ofMMP-9 andMMP-2 genes contain consensusmotifs
for NF-κB [20]. Western blot analysis demonstrated that the level of
phosphorylated IκB was rapidly downregulated by treatment of LN229
cells with 5 μM CsA in comparison to control cells (Fig. 8A and B). The
NF-κB transcriptional activity (determined using aNFκB-luciferase gene
reporter assay) was high in untreated cells and was strongly reduced in
LN229 cells exposed to 5 μM CsA. FK506 (5 μM) did not signiﬁcantly
affect NFκB transcriptional activity (Fig. 8C). The treatment of cells with
10 and 30 μM LY294002 reduced NFκB-driven transcription, however
less efﬁciently than CsA (Fig. 8D). These results conﬁrm a link between
activated Akt and activation of NFκB in LN229 cells.
3.6. MT1-MMP translocation to the cell membrane protrusions is
inhibited in CsA-treated cells
The reduction of active Akt levels and decrease ofMMP-2 enzymatic
activity occur 18 h after CsA treatment,while drugeffects onMMP-2 and
MT1-MMP expression were observed 24 h later. Therefore, a transcrip-
tion-independent mechanism of MMP-2 regulation should be consid-
ered. Therefore, we compared subcellular localization of MT1-MMP
visualized by immunoﬂuorescence with changes in cytoskeleton
rearrangements visualized by phalloidin staining of F-actin.
Fig. 4. CsA suppresses migration of LN229 cells through downregulation of PI3K/Akt pathway. Conﬂuent monolayer was scratched with a pipette tip, washed and incubated with
medium containing 5 μM CsA, 30 μM LY294002, 1 μM A443664 or DMSO (Ctrl). The cell migration was monitored for 18 h using time lapse live imaging technology. Pictures were
taken every 30 min. Tracings of movement of a few cells are shown as an example (colored lines). The graphs represent total distance covered in 24 h by each of 196 cells tested
under different conditions (n=3).
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control cells. It is particularly clear after merging MT1-MMP immuno-
ﬂuorescence with F-actin staining, which shows elongated cells with
multiple membrane protrusions enriched in actin ﬁlaments (Fig. 9). In
contrast, cells treated with 5 μM CsA were ﬂatten, more stretched and
membrane rufﬂes were not observed. In CsA-treated cultures MT1-
MMPdid not localize atmembrane protrusions. Similar pattern ofMT1-
MMP immunostaining was observed in cultures treated with 30 μM
LY294002. Taken together, these results demonstrate that CsA mod-
ulates directly tumor cell motility by blocking formation of membrane
protrusions and translocation of MT1-MMP to the membrane rufﬂes.
4. Discussion
4.1. CsA reduces glioblastoma invasion via inhibition of PI3K/Akt
signaling pathway
In the present study we demonstrated two major ﬁndings: (1) the
inhibitory effect of CsA on Akt phosphorylation resulting in consid-erable reduction of migration/invasion of human malignant glioblas-
toma cells; (2) twomechanisms possibly underlying the effect of CsA:
rapid blockade of MT1-MMP shuttling to lamellipodia leading to local
modulation of MMP-2 activity, and delayed downregulation ofMMP-2
and MT1-MMP transcription.
Several studies have shown that targeting of Akt signaling
pathway in malignant glioma cells with antisense, siRNA or small
molecule inhibitors results in downregulation of tumor invasion and
tumorigenesis [46,47]. However, effects of Akt signaling inhibition on
invasion/motility were not separated from its effect on cellular
survival/proliferation and downstream mechanisms were poorly
characterized. We used CsA at the moderate concentration of 5 μM
that did not affect cellular survival/proliferation.We demonstrate that
the observed inhibitory effect of CsA on invasion is due to interference
with PI3K/Akt signaling pathway because CsA reduced the level of
active Akt as genetic or pharmacological inhibitors of PI3K/Akt
signaling. Importantly, overexpression of constitutively active kinase
Akt (myrAkt) or constitutively high level of active Akt in T98G and
U373 cells resulting from deﬁciency in PTEN function abrogated
Fig. 5. CsA induces alterations of actin assembly in glioblastoma cells. Conﬂuent monolayer was scratched with a pipette tip, washed, treated with 5 μM CsA and ﬁxed at different
time points. (A) F-actin staining with phalloidin was performed to visualize actin organization in cells. Representative pictures of migrating cells are shown. White arrows indicate
membrane protrusions enriched in actin mashwork characteristic for motile cells. (B) Immunoblot shows changes in FAK and paxilin phsophorylation in CsA-treated cultures in a
representative experiment. B–C Immunoblots were probed with antibodies recognizing phosphorylated and total FAK and paxilin; followed by detection of β-actin on the same blot
to ensure equal loading. Densitometric evaluation of immunoblots for total and phospho-FAK is shown (means±SEM, n=3).
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demonstration of the inhibitory effect of CsA on intrinsic invasion
potential andmotility of human glioblastoma cells. Up to date, CsA has
been shown to attenuate invasion stimulated by calcium ionophore/
PMA in U251MG glioblastoma cells, by inhibiting IL-8 production in
NFκB-dependent manner [48].
Using several methods we demonstrate that 5 μM CsA reduced
invasion of human LN229 glioblastoma cells through matrigel matrix
and cell motility in a scratch assay concomitantly with down-
regulation of active Akt levels. Similarly, pharmacological inhibitors
of PI3K/Akt signaling: LY294002 (PI3K inhibitor) and A443654 (Akt
inhibitor) slowed down cell migration and reduction of velocity was
constant throughout 24 h of experiment. This is consistent with datashowing that reduction of Akt2 expression or activity in glioma cells
disturbed migration and invasion due to diminished phosphorylation
of girdin and coﬁllin, two proteins involved in actin ﬁlament
remodeling [14,15].
We identiﬁed two mechanisms of inhibition of tumor invasion and
motility: the one mediated by inhibition of PI3K/Akt-dependent
translocation of MT1-MMP to membrane protrusions and the second
one through downregulation of PI3K/Akt and NFκB-dependentMMP-2
andMT1-MMP transcription. Inhibition of Akt and FAK phosphorylation
by CsA or LY294002 resulted in rapid morphological changes:
disappearance of lamellipodia, stabilization of adhesion contacts and
cell immobilization. The observed changes in cell morphology mimic
those observed in FAK-deﬁcient cells, where inhibition of FAK signaling
Fig. 6. Reduction of MMP-2 gelatinolytic activity and modulation of MMP-2 and MT1-MMP expression by CsA. A–B. Cells untreated or cultured with 5 μM CsA, 5 μM FK506 or
LY294002. MMP-2 proteolytic activity was determined by gelatin zymography in conditioned media collected 18 or 24 h after treatment. An active MMP-2 protein (63 kDa) is
indicated an arrow; lower panel shows densitometric analysis of the levels of MMP-2 (means±SEM, n=3). C–D. Relative expressions of MMP-2 and MT1-MMP mRNAs were
determined in LN229 cells untreated or treated with 5 μM CsA by a quantitative RT-PCR with TaqMan MGB probes (means±SEM, three experiments each in triplicate).
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[8–10]. FAK autophosphorylation on Tyr-397 permits interactions
with a number of effectors, including Src-family kinases that phosphor-
ylate two FAK-interacting proteins, Crk-associated substrate (CAS) and
paxillin, which results in regulation of Rho-family GTPases and
phosphatidylinositol 3-kinase [8–10]. Downregulation of FAK signaling
preceding morphological alterations and cell immobilization is consis-
tentwith a possible role of FAK in phosphorylation of paxilin at adhesion
contacts and modulation its interactions with adaptor proteins such as
ezrin.
A second, delayed consequence of CsA treatment is downregula-
tion of MMP-2 activity. While MMP-2 activity was easily detected by
gelatin zymography in LN229 cells, we did not detect the activity
corresponding to MMP-9. However, some studies described detection
of MMP-2 and MMP-9 in glioblastoma cell lines, others studies failed
to detect MMP-9 expression (f.e. in T98G cells) [26]. Upregulated
expression of MMP-2 andMT1-MMP correlates with increased glioma
invasion and tumor grade [18,21]. Involvement of Akt in regulation of
MMP-2 and MMP-9 activities has been demonstrated in rat C6 glioma
cells, in which transfection of dominant-negative or antisense AKT2
constructs reduced the production of MMP-2 and MMP-9, migration
and invasion in vitro [14] and in intracranial gliomas in vivo [15]. Our
results demonstrate that both CsA and LY294002 decreased MMP-2
gelatinolytic activity in human glioblastoma cells.
Activity of MMPs can be regulated at the level ofMMP-2,MT1-MMP
or TIMP-2 transcription and production, as well as secretion or
activation of pro-MMP-2 by MT1-MMP and TIMP-2 at the cell
membrane surface [14,17,20,27]. However, NFκB transcription factorhas been postulated as a regulator of MT1-MMP expression, its
participation has been demonstrated only in human dermal and
rabbit synovial ﬁbroblasts [49,50]. Studies with interfering antibody
antip65 NFκB showed reduction of MMP-9, urokinase-type plasmin-
ogen activator activities and invasion of glioblastoma cells [51,52].
Similarly, although Akt can phosphorylate and activate IκB kinase
regulating phosphorylation of IκB that is crucial for NFκB activation
[53–55], this action was not shown in glioma cells.
We demonstrate that treatment of glioblastoma cells with CsA or
LY294002 reduced the level of phosphorylated IκB and NFκB-driven
transcription. Thus, we postulate that downregulation of Akt activity
by CsA or LY294002 leads to reduction of IκB phosphorylation, its
stabilization, inhibition of NFκB transcriptional activity and reduction
of NFκB-dependentMMP-2 target gene expression. The NFκB inhibitor
– BAY11-7082 – strongly reduced the MMP-2 expression in LN229
cells (Fig. 7C). FK506 (an unrelated calcineurin inhibitor) which did
not affect NFκB activity, had no effect on MMP-2 activity. It suggests
that mechanism of CsA action is calcineurin-inhibition independent.
4.2. Impairment of MT1-MMP shuttling to invadopodia may locally
inhibit MMP-2
MT1-MMP is a cell surface activator of pro-MMP-2 and has been
implicated in the proteolytic cleavage of many extracellular and
membrane-associated substrates. MT1-MMP activation is complex
and involves regulation of MT1-MMP expression, trafﬁcking, and/or
endocytosis after stimulation by multiple factors [56,57]. The
enhanced surface expression of MT1-MMP in lamellipodia-like
Fig. 7. Contribution of Akt and NFκB in regulation of MMP2 and MT1-MMP expression. Relative expressions of MMP-2 and MT1-MMP mRNAs in LN229 treated for 24 h with 10 or
30 μM LY294002 (A), transfected with plasmids coding for mutated Akt (ΔPHAkt or K179MAkt) (B) or incubated for 24 h with BAY11-7082 (C). Relative expression of MMP-2 and
MT1-MMP mRNAs was determined using quantitative RT-PCR with TaqMan MGB probes; data show means±SEM of three experiments in A, C, and two experiments in B (each in
triplicate). (D) Representative immunoblot shows the levels of MMP-2 and MT1-MMP proteins in glioblastoma cells exposed for 48 h to 5 μM CsA, 10 μM BAY11-7082 and 30 μM
LY294002; similar results were found in three experiments.
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contrary to CsA-treated cultures, where MT1-MMP immunoﬂuores-
cence was diffused (Fig. 9). Moreover, CsA-treated cells did not form
cell protrusions. F-actin staining revealed that in contrast to control
cells, having multiple membrane protrusions and polarized lamelli-
podia, treated cells exhibited more stretched cell shape with strong
actin stress ﬁbers. A growing evidence demonstrates an importance
of MT1-MMP trafﬁcking for local modulation of protease activity in
invadopodia [58]. However, overall inhibition of MMP-2 activity by
CsA was 40% (in gel zymography assay), disruption of local activity
of MMP-2 at invadopodia together with stabilization of adhesion
contacts resulting in cell immobilization may produce inhibitory
mechanisms sufﬁciently affecting cell migration and invasion.
5. Conclusions
• We show here that CsA, through a mechanism yet unknown but
independent of calcineurin inhibition, downregulates phsophoryla-
tion of Akt and FAK, as well as downstream signaling in malignantglioblastoma cells that result in impairment of cell motility/invasion
and reduction of MMP-2 activity. • More importantly, this study
demonstrates that PI3K/Akt signaling contributes to translocation of
MT1-MMP that can locally inﬂuence MMP-2 proteolytic activity and
facilitate formation of invadopodia. • Furthermore, we established
that the expression of MMP-2 is regulated in Akt- and NFκB-
dependent manner, while MT1-MMP in Akt-dependent in glioblasto-
ma cells. Understanding of molecular determinants of glioblastoma
cell invasion and proven anti-tumor efﬁcacy of CsA in animal model
help to move forward to translational research.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2011.01.020.
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